Global Immunoassay Reagents and Devices Market is expected to grow with the CAGR of 4.9% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:
Access Full Report @ https://www.databridgemarketresearch.com/es/reports/global-immunoassay-reagents-and-devices-market
Global immunoassay reagents and devices market is a highly fragmented market, which includes large number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in global immunoassay reagents and devices market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, business expansion, award and recognition into the market. This has helped companies to maximize the sales with enhanced product portfolio. For instance, in April 2021, F. Hoffmann-La Roche Ltd launched five new intended uses for two key cardiac biomarkers using the Elecsys technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks (cTnT-hs) and better manage heart failure (NT-proBNP). This will help the company to improve its product portfolio and enhance its market share.
F. Hoffmann-La Roche Ltd is the dominating player in global immunoassay reagents and devices market. The other key players existing in the immunoassay reagents and devices market are Siemens, Randox Laboratories Ltd., Abbott, Bio-Rad Laboratories, Inc., Merck KGaA, Beckman Coulter, Inc. (a subsidiary of Danaher), Sysmex Corporation, bioMérieux SA, Thermo Fisher Scientific, Inc., BD, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., DiaSorin S.p.A, Ortho Clinical Diagnostics, QIAGEN, Quidel Corporation, BioCheck, Inc., Bio-Techne, PerkinElmer Inc., Agilent Technologies, Inc., Luminex Corporation, MESO SCALE DIAGNOSTICS, LLC among others.
F. Hoffmann-La Roche Ltd:
F. Hoffmann-La Roche Ltd is headquartered in Basel, Switzerland and was founded in 1896. The company deals in developing, manufacturing pharmaceutical and diagnostics products. The company operates in business segments namely pharmaceuticals and diagnostics out of which diagnostics is the market focused segment. The company has wide range of products under categories such as pharmaceuticals, solutions for diagnostics and products for researchers among which solutions for diagnostics is the market focused category.
For instance,
- In June 2021, F. Hoffmann-La Roche Ltd received CE mark for its SARS-CoV-2 Antigen Self-Test Nasal for at-home testing. This will help the company to improve its speed and efficiency in diagnostic solution.
The company has wide presence across the Europe, Asia-Pacific, Americas and Middle East and Africa and generates revenue through various subsidiary companies such as Genentech, Inc. (U.S.), Roche Diagnostics Limited (U.K.), Chugai Pharmaceutical Co. (Japan), Flatiron Health, Inc. (U.S.), Ventana Medical Systems (U.S.), Kapa Biosystems, Inc. (U.S.) among others.
Abbott:
Abbott is headquartered in Illinois, U.S. and was founded in 1888. The company manufactures and provides products and services for cardio metabolic disease, infectious disease and toxicology. The company operates in business segments namely established pharmaceuticals, nutritionals, diagnostic, cardiovascular and neuromodulation out of which diagnostics is the market focused segment. The company has wide range of brands under categories such as accelerator, architect, CELL-DYN, Alinity and AlinIQ among which architect is the market focused category.
For instance,
- In May 2021, Abbott announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AFib) and heart failure. The first-of-its-kind trial aims to provide new insights into more effective treatment for patients with AFib and heart failure, a complex combination that has historically presented significant challenges to physicians.
The company has presence across the Europe, Asia-Pacific, Americas and Middle East and Africa and generates revenue through various subsidiary companies such as Abbott Administration Inc. (Delaware), Abbott Cardiovascular Systems Inc. (California), Abbott Home Infusion Services of New York, Inc. (New York), Abbott Laboratories (Puerto Rico) Incorporated, EAS Australia Pty Ltd (Australia), Abbott (Cambodia) LLC, Abbott Laboratories A/S (Denmark) among others.
DiaSorin S.p.A:
DiaSorin S.p.A. is headquartered in Saluggia, Italy and was founded in 1968. The company is focused in manufacturing of products in immunodiagnostics and molecular diagnostics segment. The company operates in business segment namely diagnostic kits. The company has wide range of products under categories such as CLIA systems and ELISA systems.
For instance,
- In January 2021, DiaSorin S.p.A launched LIAISON SARS-CoV-2 TrimericS IgG test which is used for determining the amount of IgG antibodies present in the body against SARS-CoV-2 in order to determine the efficacy of COVID-19 vaccines. This new product helped the company to play an important role in the long-term fight against COVID-19.
The company has presence across North America and Europe.
